In vitro, TGF-β can inhibit ability of myeloid cells to take up antigen and secrete cytokines and chemokines, and blockade of TGF-β signaling has been shown to improve the efficacy of DC cancer vaccines 57, 58. This evidence concerns the gene TGFB1 and cancer.